For the transition into the clinic, it is necessary to proceed with the validation of the method in the preclinical phase and invest in this research pathology, which, although rare, shares pathogenetic aspects with SMA and therefore also the susceptibility of treatment for SMARD1 patients. The gene discussed is IGHMBP2; the disease is proximal spinal muscular atrophy.